Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CYPH. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CYPH is a Sell candidate.
CYPH stock price ended at $0.82 on 星期一, after dropping 1.20%
On the latest trading day Jan 26, 2026, the stock price of CYPH fell by 1.20%, dropping from $0.80 to $0.82. During the session, the stock saw a volatility of 8.97%, with prices oscillating between a daily low of $0.78 and a high of $0.85. On the latest trading day, the trading volume for CYPH decreased by 1.7M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.5M shares were traded, with a market value of approximately $46.4M.